This medicine represents the single greatest therapeutic advancement in the history of CF, offering a treatment for the underlying cause of the disease that could eventually benefit more than 90 percent of people with CF.
Drug Targets the Underlying Cause of the Disease in People with the Most Common CF Mutation
July 2, 2015
|
5 min read
March 18, 2015
|
3 min read
CF Foundation Provided Scientific, Clinical and Significant Funding Support in Drug Development Process
June 24, 2014
|
5 min read
Kalydeco Marks the Latest Success of the Cystic Fibrosis Foundation’s Venture Philanthropy Model
Jan. 31, 2012
|
5 min read